Soricimed Biopharma, a private clinical stage company, has started the treatment of their first patient in a Phase I clinical trial of anti-cancer agent SOR-C13, at the Juravinski Cancer Centre in Hamilton, Ontario, Canada.

The multicentre, open-label study, which will take place at cancer centres in both Canada and the US, is designed to assess safety and tolerability of SOR-C13 in patients with advanced cancer tumours, with a focus on ovarian cancers.

"Unlike chemotherapy, the cancer treatment is highly targeted, affecting only cancer cells."

The dose escalation study will also assess pharmacokinetics, biomarkers and initial evidence for efficacy.

Soricimed Biopharma chairman and chief scientific officer Jack Stewart said that unlike chemotherapy, the company’s cancer treatment is highly targeted, affecting only cancer cells.

"Healthy cells are not affected. It’s also a biologic, meaning it’s derived from a naturally occurring peptide that when broken down produces amino acids that can be reused by the body," Stewart said.

"As a result, and this is key, there have been virtually no side effects demonstrated in our pre-clinical studies."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects to carry out Phase I trials till February 2013 and to release interim results later in 2012. If results are successful, further clinical trials will follow.

SOR-C13 works by inhibiting a non-voltage gated calcium channel found in epithelial cancers such as ovarian, breast and prostate.

Pre-clinical studies demonstrated that SOR-C13 induces apoptosis (cell death), inhibits cell proliferation and reduces tumour volume while minimising side effects associated with typical chemotherapy.